title: [Design and birth of drugs].
abstract: Today the design of new clinical entities uses highly sophisticated techniques. This design is a step by step procedure: first selection and validation of the therapeutic targets, where the contribution of genomics is very important; then, setting up the different screening tests. This step permits to detect the potentially active molecules, which will be optimised, before being tested in healthy volunteers and then in patients.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Maffrand
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Lehner
authors.forename: Gérard
authors.initials: G
authors.lastname: Le Fur
mesh_terms: D002986:Clinical Trials as Topic; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D023281:Genomics; D006801:Humans